Almirall has launched Sativex oro-mucosal spray for the treatment of spasticity in multiple sclerosis patients in Spain. Sativex is an endocannabinoid modulator that contains THC and cannabidiol developed and manufactured by GW Pharmaceuticals.
According to the company approximately 75% of the 40,000 MS patients in Spain suffer from spasticity. The product will be available at hospital pharmacies and will be reimbursed 100% by the National Health System.
Almirall holds European marketing rights, except in the UK. Bayer holds marketing rights in the UK and Canada, while Otsuka has an exclusive license to develop and market Sativex in the US.
Sativex is also in Phase 3 development for the treatment of cancer pain.
Read the company’s press release.
